BeiGene, Ltd. (BGNE)
Pre-Market:
| Previous Close | 171.27 |
| Open | 167.80 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's Range | 160.04 - 171.31 |
| 52 Week Range | 118.18 - 426.56 |
| Volume | |
| Avg. Volume | 284,419 |
| Market Cap | 17.845B |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -20.05 |
| Earnings Date | Aug 08, 2018 - Aug 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 318.06 |
- Zacks
BeiGene, Ltd. (BGNE) Soars 15.5%: Is Further Upside Left in the Stock?
BeiGene, Ltd. (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Motley Fool
Why Shares of BeiGene Popped Today
BeiGene's (NASDAQ: BGNE) shares were up by more than 13% on Tuesday at 2:50 p.m. ET thanks to a regulatory body in China accepting one of the company's supplemental biologics licensing application filings for a new indication for its drug tislelizumab. The Center for Drug Evaluation (CDE) will now evaluate whether tislelizumab is sufficiently safe and effective to treat metastatic gastric junction adenocarcinoma in conjunction with chemotherapy for patients whose tumors express the PD-1 biomarker, potentially giving BeiGene the green light for an expansion of its commercialization in China. If regulators ultimately opt to approve the company's application, it'll be the 10th indication for tislelizumab in China, which speaks to its versatility as a cancer medicine as well as its money-making potential.
- Business Wire
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING, June 21, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for the company’s anti-PD-1 inh
